Benitec Biopharma Inc. (BNTC)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch BNTC
See up to 3 months of BNTC. The 7-day demo opens the 1M and 3M ranges and puts BNTC on your watchlist.
Start 7-day demoLatest BNTC insider trades
About Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc. is an SEC registrant, filing under CIK 0001808898, classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
BNTC Form 4 activity by transaction type, last 90 days
No Form 4 activity for BNTC in the last 90 days.
BNTC insider transactions (Form 4)
4224 Form 4 filings on record, the earliest from Nov 21, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| J. Kevin Buchi | Gift | Common Stock | 51,813 | $0.00 | - | |
| David Matthew Friedman | Grant or award | Options (right to buy) | 35,000 footnote F1 | $0.00 | - | |
| ||||||
| Sharon Mates - Director | Grant or award | Options (right to buy) | 31,500 | $0.00 | - | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 42,600 footnote F2 | $12.85 footnote F2 | $547K | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 7,400 footnote F3 | $12.85 footnote F3 | $95K | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 14,320 footnote F4 | $13.10 footnote F4 | $188K | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 2,516 footnote F5 | $13.10 footnote F5 | $33K | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 65,800 footnote F6 | $13.44 footnote F6 | $884K | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 11,587 footnote F7 | $13.44 footnote F7 | $156K | |
| ||||||
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 8,700 footnote F2 | $11.24 footnote F2 | $98K | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 1,515 footnote F3 | $11.24 footnote F3 | $17K | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 13,950 footnote F4 | $11.48 footnote F4 | $160K | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 2,434 footnote F5 | $11.48 footnote F5 | $28K | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 16,650 footnote F6 | $12.08 footnote F6 | $201K | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 2,892 footnote F7 | $12.08 footnote F7 | $35K | |
| ||||||
| Kishan Mehta - Director | Grant or award | Options (right to buy) | 35,000 footnote F1 | $0.00 | - | |
| ||||||
| Peter Francis - Director | Grant or award | Options (right to buy) | 35,000 | $0.00 | - | |
| Sharon Mates - Director | Grant or award | Options (right to buy) | 3,500 | $0.00 | - | |
| Edward F. Smith - Director | Grant or award | Options (right to buy) | 35,000 | $0.00 | - | |
| J. Kevin Buchi - Director | Grant or award | Options (right to buy) | 35,000 | $0.00 | - | |
| Sophie Mukadam - Officer | Grant or award | Options (right to buy) | 500,000 | $0.00 | - | |
| Jerel A. Banks - Officer | Grant or award | Options (right to buy) | 450,000 | $0.00 | - | |
| Megan Boston - Officer | Grant or award | Options (right to buy) | 200,000 | $0.00 | - | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 730,370 footnote F2 | $13.50 footnote F2 | $9.86M | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 751,111 footnote F3 | $13.50 footnote F3 | $10.14M | |
| ||||||
| Sharon Mates - Director | Grant or award | Options (right to buy) | 28,517 | $0.00 | - | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 24,360 | $10.98 | $267K | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 3,142 | $10.98 | $34K | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 17,730 | $11.25 | $199K | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 2,288 | $11.25 | $26K | |
| Kishan Mehta - Director | Grant or award | Options (right to buy) | 35,000 | $0.00 | - | |
| Jerel A. Banks - Officer | Grant or award | Options (right to buy) | 2,310,000 | $0.00 | - | |
| Megan Boston - Officer | Grant or award | Options (right to buy) | 720,000 | $0.00 | - | |
| Peter Francis - Director | Grant or award | Options (right to buy) | 35,000 | $0.00 | - | |
| Edward F. Smith - Director | Grant or award | Options (right to buy) | 35,000 | $0.00 | - | |
| J. Kevin Buchi - Director | Grant or award | Options (right to buy) | 35,000 | $0.00 | - | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 37,190 | $9.60 | $357K | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 4,810 | $9.60 | $46K | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 12,430 | $9.73 | $121K | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 1,570 | $9.73 | $15K | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 24,360 | $10.22 | $249K | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Open-market purchase | Common stock, par value $0.0001 per share | 3,076 | $10.22 | $31K | |
Item 7.01, 9.01
Item 4.01
Item 4.01, 9.01
Item 2.02, 9.01
BNTC insider trading FAQ
What is the latest insider trade for BNTC?
Benitec Biopharma Inc. (BNTC) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-06-30. The full record for BNTC runs to 24 Form 4 filings, the earliest from 2024-11-21. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying BNTC stock?
No insider purchases of BNTC were filed in the last 90 days. 24 purchases are on record for this company.
How many insiders are selling BNTC stock?
No insider sales of BNTC were filed in the last 90 days.
Where can I see BNTC SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects BNTC Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - J. Kevin Buchi view on EDGAR
- - David Matthew Friedman view on EDGAR
- - Sharon Mates view on EDGAR
- - SUVRETTA CAPITAL MANAGEMENT, LLC view on EDGAR
- - SUVRETTA CAPITAL MANAGEMENT, LLC view on EDGAR
- - Kishan Mehta view on EDGAR
- - Peter Francis view on EDGAR
- - Sharon Mates view on EDGAR
- - Edward F. Smith view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where BNTC's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow BNTC with a 7-day demo
- BNTC on your watchlist
- Every BNTC Form 4 filing on record
- Up to 3 months of BNTC price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
